Goldman Sachs Upgrades Nokia to Neutral, Raises Price Target to EUR 8

Nuvation Bio Inc. (NUVB) and Eisai announced the European Medicines Agency (EMA) validation of the Marketing Authorisation Application (MAA) for Taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer. The EMA validation builds on the January 2026 exclusive licensing deal between Eisai and Nuvation Bio for Europe and select regions outside the US, China, and Japan.